{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T10:59:59Z","timestamp":1764413999549,"version":"3.44.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01MH121397"],"award-info":[{"award-number":["R01MH121397"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["General Hospital Psychiatry"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.genhosppsych.2023.06.012","type":"journal-article","created":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T19:11:28Z","timestamp":1687461088000},"page":"268-270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Safety of Glecaprevir\/Pibrentasvir for hepatitis C in patients with posttraumatic stress disorder: A post-marketing surveillance study"],"prefix":"10.1016","volume":"84","author":[{"given":"Brian","family":"Shiner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenna A.","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luke","family":"Rozema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica E.","family":"Hoyt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley V.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaimie L.","family":"Gradus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.genhosppsych.2023.06.012_bb0005","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.biopsych.2017.03.007","article-title":"It is time to address the crisis in the pharmacotherapy of posttraumatic stress disorder: a consensus statement of the PTSD psychopharmacology working group","volume":"82","author":"Krystal","year":"2017","journal-title":"Biol Psychiatry"},{"issue":"7","key":"10.1016\/j.genhosppsych.2023.06.012_bb0010","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.biopsych.2021.10.008","article-title":"Mining clinical data for novel posttraumatic stress disorder medications","volume":"91","author":"Shiner","year":"2022","journal-title":"Biol Psychiatry"},{"issue":"9","key":"10.1016\/j.genhosppsych.2023.06.012_bb0015","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1093\/aje\/kwac104","article-title":"Comparative effectiveness of direct-acting antivirals for posttraumatic stress disorder in veterans affairs patients with hepatitis C virus infection","volume":"191","author":"Shiner","year":"2022","journal-title":"Am J Epidemiol"},{"issue":"11","key":"10.1016\/j.genhosppsych.2023.06.012_bb0020","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1037\/pas0000254","article-title":"Psychometric properties of the PTSD checklist for diagnostic and statistical manual of mental disorders-fifth edition (PCL-5) in veterans","volume":"28","author":"Bovin","year":"2016","journal-title":"Psychol Assess"},{"issue":"10","key":"10.1016\/j.genhosppsych.2023.06.012_bb0025","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1093\/cid\/ciz022","article-title":"Safety and pharmacokinetics of Glecaprevir\/Pibrentasvir in adults with chronic genotype 1-6 hepatitis C virus infections and compensated liver disease","volume":"69","author":"Gane","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.genhosppsych.2023.06.012_bb0030","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.jhep.2020.01.025","article-title":"Real-world effectiveness and safety of glecaprevir\/pibrentasvir for the treatment of patients with chronic HCV infection: a meta-analysis","volume":"72","author":"Lampertico","year":"2020","journal-title":"J Hepatol"},{"issue":"15","key":"10.1016\/j.genhosppsych.2023.06.012_bb0035","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","article-title":"Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment","volume":"377","author":"Gane","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.genhosppsych.2023.06.012_bb0040","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1053\/j.gastro.2016.05.049","article-title":"Effectiveness of Sofosbuvir, Ledipasvir\/Sofosbuvir, or Paritaprevir\/ritonavir\/Ombitasvir and Dasabuvir regimens for treatment of patients with hepatitis C in the veterans affairs National Health Care System","volume":"151","author":"Ioannou","year":"2016","journal-title":"Gastroenterology."},{"author":"Watts","key":"10.1016\/j.genhosppsych.2023.06.012_bb0045"},{"issue":"240","key":"10.1016\/j.genhosppsych.2023.06.012_bb0050","first-page":"68301","article-title":"Pilot program for dental health care access","volume":"84","author":"Martin","year":"2019","journal-title":"Fed Regist"}],"container-title":["General Hospital Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163834323001093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163834323001093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:57:31Z","timestamp":1759013851000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163834323001093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":10,"alternative-id":["S0163834323001093"],"URL":"https:\/\/doi.org\/10.1016\/j.genhosppsych.2023.06.012","relation":{},"ISSN":["0163-8343"],"issn-type":[{"type":"print","value":"0163-8343"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of Glecaprevir\/Pibrentasvir for hepatitis C in patients with posttraumatic stress disorder: A post-marketing surveillance study","name":"articletitle","label":"Article Title"},{"value":"General Hospital Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.genhosppsych.2023.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}